生产企业：Merck & Co., Inc.
First FDA-approved once-daily oral PCSK9 inhibitor (novel macrocyclic peptide) for reducing LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia; developed by Merck & Co., Inc.
First FDA-approved once-daily oral PCSK9 inhibitor (novel macrocyclic peptide) for reducing LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia; developed by Merck & Co., Inc.
Oral PCSK9 inhibitor; a novel macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors, increasing LDL-receptor recycling to lower LDL-C.
As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
